Back to the future: Testing in disseminated intravascular coagulation

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 8, 2005, Pages 535-542

  Toh, Cheng Hock ^a,b   Downey, Colin ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Activated protein c; Disseminated intravascular coagulation; Laboratory tests; Thrombin

Indexed keywords

MOLECULAR MARKER;

ASSAY; BLOOD CLOTTING; BLOOD CLOTTING TIME; CELL ACTIVATION; CELL FUNCTION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; IN VIVO STUDY; INFLAMMATION; LABORATORY TEST; MEDICAL TECHNOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; THROMBIN TIME; THROMBOSIS;

EID: 27844439875     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000187905.54087.91     Document Type: Review

References (61)

1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriquez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
2. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt DT, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2:1924-1933.
3. Aoki N, Matsuda T, Saito H, Takatsuki K, Okajima K, Takahashi H, et al. A comparative double-blind randomised trial of activated protein C with unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 2002; 75:540-547.
4. Astiz ME, Rackow EC. Septic shock. Lancet 1998; 351:1501-1505.
5. Giles AR, Nesheim ME, Mann KG. Studies of factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest 1984; 74:2219-2225.
6. Gando S, Nanzaki S, Sasaki S, Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998; 79:1111-1115.
7. Mackman N. Role of tissue factor in haemostasis, thrombosis and vascular development. Arterioscler Thromb Vasc Biol 2004; 24:1015-1022.
8. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93:10212-10216.
9. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets trigger an inflammatory reaction of endothelial cells. Nature 1998; 391:591-594.
10. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181.
11. Van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W. Progress of fibrinolysis during tumor-necrosis factor infusions in humans: concomitant increase in tissue-type plasminogen-activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76:2284-2289.
12. Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis 2001; 12:1-8.
13. Biro E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, et al. Human cell-derived microparticles promote thrombus formation in a tissue factor-dependent manner. J Thromb Haemost 2004; 1:2561-2568.
14. Von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86:3035-3042.
15. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992; 101:594-596.
16. 2- macroglobulin in patients with disseminated intravascular coagulation. Thromb Haemost 1993; 69:448-453.
17. Samis J, Kam E, Nesheim ME, Giles AR. Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function. Blood 1998; 92:1287-1296.
18. Kalafatis M, Swords NA, Rand MD, Mann KG. Membrane dependant reactions in blood coagulation: role of the vitamin K enzyme complexes. Biochim Biophys Acta 1994; 1227:113-129.
19. Nesheim ME, Tracy RP, Mann KG. 'Clotspeed,' a mathematical simulation of the functional properties of prothrombinase. J Biol Chem 1984; 259:1447-1453.
20. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylsesrine vesicles bypasses factor VIII in vivo. Br J Haemat 1988; 69:491-497.
21. Satta N, Toti F, Feugas O, Bohbot A, Dachary-Prigent J, Eschwege V, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane associated procoagulant activities and adhesion molecules after stimulation with lipopolysaccharide. J Immunol 1994; 153:3245-3255.
22. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1:1655-1662.
23. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 1989; 30:39-49.
24. Dennis MW, Downey C, Brufatto N, Nesheim ME, Stevenson K, Toh CH. Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein. Thromb Haemost 2004; 9:522-530.
25. Toh CH, Samis J, Downey C, Walker J, Becker L, Bruffato N, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a calcium dependant complex of C-reactive protein with very-low-density-lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002; 100:2522-2529.
26. Hasty AH, Linton MF, Swift LL, Fazio S. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J Lipid Res 1999; 40:1529-1538.
27. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103:219-227.
28. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110:880-885.
29. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196:565-577.
30. Coughlin SR. Thrombin signalling and protease activated receptors. Nature 2000; 407:258-264.
31. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000; 191:455-462.
32. Johnson K, Choi Y, de Groot E, Samuels I, Creasey A, Innis M. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160:5130-5135.
33. Connolly TM, Condra C, Feng DM, Cook JJ, Staneiri MT, Reilly CF, et al. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 1994; 72:627-633.
34. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765-3777.
35. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349:1912-1913.
36. Toh CH, Dennis MW. Disseminated intravascular coagulation: old disease, new hope. BMJ 2003; 327:974-977.
37. Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation: a study of 118 cases. Thromb Haemost 1978; 39:122-134.
38. Olson JD, Kaufman HH, Moake J, O'Gorman TW, Hoots K, Wagner K, et al. The incidence and significance of hemostatic abnormalities in patients with head injuries. Neurosurgery 1989; 24:825-831.
39. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998; 24:3-18.
40. Raimondi P, Bongard O, de Moerloose P, Reber G, Waldvogel F. D-Dimer plasma concentration in various clinical conditions. Thromb Res 1993; 69:125-130.
41. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation: findings in 346 patients. Thromb Haemost 1980; 43:28-33.
42. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Biol Haematol 1983; 49:265-275.
43. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995; 74:848-852.
44. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327-1330.
45. Wada H, Gabazza EC, Asakura H, Koike K, Okamoto K, Maruyama I, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Haemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003; 74:17-22.
46. Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2004; 15:1-6.
47. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, et al. Coagulation activation and tissue necrosis in menigococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73:15-20.
48. Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1993; 43:190-194.
49. Liaw PCY, Ferrell G, Esmon CT. A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost 2003; 1:662-670.
50. Dempfle CE, Zips S, Ergul H, Heene DL. The fibrin assay comparison trial (FACT): correlation of soluble fibrin assays with D-dimer. Thromb Haemost 2001; 86:1204-1209.
51. Dempfle CE, Pfitzner SA, Dollman M, Huck K, Stehle G, Heene DL. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemost 1995; 74:673-679.
52. Zuckerman L, Cohen E, Vager JP, Woodword E, Kaprini JA. Comparison of thromboelastography with common coagulation tests. Thromb Haemost 1981; 46:752-756.
53. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77:38-46.
54. Downey C, Kazmi R, Toh CH. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol 1997; 98:68-73.
55. Toh CH, Downey C, Dwyre L. Thromboplastin sensitivity in waveform analysis. Thromb Haemost 2000; 84:517-518.
56. Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998; 80:65-69.
57. Toh CH, Ticknor LO, Downey C, Giles AR, Paton R, Wenstone R. Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Intensive Care Med 2003; 29:55-61.
58. Dempfle CE, Lorenz S, Smolinski M, Wurst M, West S, Houdijk WP, et al. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Crit Care Med 2004; 32:520-524.
59. Smith EY, Charles LA, Van Cott EM. Biphasic activated partial thromboplastin time waveform and adverse events in non-intensive care unit patients. Am J Clin Pathol 2004; 121:138-141.
60. Fernandes B, Giles AR. An abnormal activated partial thromboplastin time clotting waveform is associated with high mortality and a procoagulant state. Lab Hematol 2003; 9:138-142.
61. Samis JA, Stewart KA, Toh CH, Day A, Downey C, Nesheim ME. Temporal changes in factors associated with neutrophil elastase and coagulation in intensive care patients with a biphasic waveform and disseminated intravascular coagulation. J Thromb Haemost 2004; 2:1535-1544.